Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy J Price

Showing results (131-140 of 153) with videos related to

Pageof 16
Sort By:
Cancer Medicine|October 16, 2018
Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancerDaniel Shepshelovich, Amanda R Townsend, Osvaldo Espin-Garcia, et al.
The New England Journal of Medicine|October 24, 2008
K-ras mutations and benefit from cetuximab in advanced colorectal cancerChristos S Karapetis, Shirin Khambata-Ford, Derek J Jonker, et al.
Scientific Reports|January 25, 2022
VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancerFiona Chionh, Val Gebski, Sheren J Al-Obaidi, et al.
Neuroendocrinology|September 1, 2022
Australasian Consensus Statement on the Identification, Prevention, and Management of Hormonal Crises in Patients with Neuroendocrine Neoplasms Undergoing Peptide Receptor Radionuclide TherapyMinmin Li, David L Chan, Gonzalo Tapia Rico, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2010
Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX StudyNiall C Tebbutt, Kate Wilson, Val J Gebski, et al.
Clinical Genetics|September 20, 2021
RNF43 pathogenic Germline variant in a family with colorectal cancerReger R Mikaeel, Joanne P Young, Yun Li, et al.
Cancers|December 30, 2025
Identification of Novel Susceptibility Genes for Early-Onset Colorectal Cancer Through Germline Rare Variant Burden TestingRuocen Song, Reger R Mikaeel, Zhongping He, et al.
BMC Gastroenterology|April 21, 2017
Findings in young adults at colonoscopy from a hospital service database auditStephanie Wong, Ilmars Lidums, Christophe Rosty, et al.
Clinical Colorectal Cancer|September 13, 2023
Plasma Cetuximab Concentrations Correlate With Survival in Patients With Advanced KRAS Wild Type Colorectal CancerDi Maria Jiang, Shruti Parshad, Luna Zhan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2016
Fc-γ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal CancerGeoffrey Liu, Dongsheng Tu, Marcia Lewis, et al.
Pageof 16

Showing results (131-140 of 153) with videos related to

Sort By:
Pageof 16
Cancer Medicine|October 16, 2018
Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancerDaniel Shepshelovich, Amanda R Townsend, Osvaldo Espin-Garcia, et al.
The New England Journal of Medicine|October 24, 2008
K-ras mutations and benefit from cetuximab in advanced colorectal cancerChristos S Karapetis, Shirin Khambata-Ford, Derek J Jonker, et al.
Scientific Reports|January 25, 2022
VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancerFiona Chionh, Val Gebski, Sheren J Al-Obaidi, et al.
Neuroendocrinology|September 1, 2022
Australasian Consensus Statement on the Identification, Prevention, and Management of Hormonal Crises in Patients with Neuroendocrine Neoplasms Undergoing Peptide Receptor Radionuclide TherapyMinmin Li, David L Chan, Gonzalo Tapia Rico, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2010
Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX StudyNiall C Tebbutt, Kate Wilson, Val J Gebski, et al.
Clinical Genetics|September 20, 2021
RNF43 pathogenic Germline variant in a family with colorectal cancerReger R Mikaeel, Joanne P Young, Yun Li, et al.
Cancers|December 30, 2025
Identification of Novel Susceptibility Genes for Early-Onset Colorectal Cancer Through Germline Rare Variant Burden TestingRuocen Song, Reger R Mikaeel, Zhongping He, et al.
BMC Gastroenterology|April 21, 2017
Findings in young adults at colonoscopy from a hospital service database auditStephanie Wong, Ilmars Lidums, Christophe Rosty, et al.
Clinical Colorectal Cancer|September 13, 2023
Plasma Cetuximab Concentrations Correlate With Survival in Patients With Advanced KRAS Wild Type Colorectal CancerDi Maria Jiang, Shruti Parshad, Luna Zhan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2016
Fc-γ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal CancerGeoffrey Liu, Dongsheng Tu, Marcia Lewis, et al.
Pageof 16